Shattuck Labs (STTK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual Meeting of Stockholders scheduled for May 28, 2026, to be held virtually at 11:30 AM Eastern Time.
Stockholders of record as of April 2, 2026, are eligible to participate and vote.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report, are available online or by request.
Voting matters and shareholder proposals
Election of three Class III director nominees to serve until the 2029 Annual Meeting: Taylor Schreiber, Helen M. Boudreau, and Clay Siegall.
Ratification of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.
Advisory vote on the compensation of named executive officers (say-on-pay).
Advisory vote on the frequency of future say-on-pay votes.
Approval of an amendment and restatement of the 2020 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends voting "FOR" each director nominee and all proposals except Proposal 4, where "1 YEAR" is recommended for the frequency of say-on-pay votes.
Latest events from Shattuck Labs
- Lead DR3 antibody SL-325 shows promise for IBD with strong safety and low immunogenicity.STTK
Corporate presentation14 Jul 2026 - DR3 blocking antibodies for IBD aim to surpass TL1A blockers in efficacy and safety, with key trials imminent.STTK
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - SL-325 showed durable DR3 blockade, low immunogenicity, and is advancing to phase IIb in Crohn's.STTK
Study result8 Jun 2026 - SL-325, a first-in-class DR3 antibody for IBD, advances with strong preclinical data and funding.STTK
Corporate presentation7 May 2026 - SL-325 Phase 1 enrollment completed; net loss rose to $14.8M, cash runway into 2029.STTK
Q1 20267 May 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and equity plan changes.STTK
Proxy filing8 Apr 2026 - SL-325 offers a novel, potent approach to IBD by targeting DR3, with Phase 2 trials planned.STTK
Corporate presentation5 Mar 2026 - SL-325 clinical progress and a strengthened cash position extend operational runway into 2029.STTK
Q4 20255 Mar 2026 - SL325, a DR3-targeting antibody, advances to clinical trials for IBD with IND planned mid-2025.STTK
Piper Sandler 36th Annual Healthcare Conference3 Feb 2026